What Advanced Oncotherapy does

Advanced Oncotherapy is a London-based, publicly listed medical technology company (LSE: AVO) founded in 2012 that develops advanced radiotherapy systems for the treatment of common and rare cancers. The company's stated positioning is in the particle therapy / linear particle accelerator segment, an area addressing a global particle therapy market projected at $2.44 billion by 2030 (12.4% CAGR), a broader linear particle accelerators market projected at $3.53 billion by 2030 (5.1% CAGR), and a CyberKnife-adjacent market projected at $1.56 billion by 2030 (16.6% CAGR). Its technological foundation traces to the 2013 acquisition of ADAM SA, an undisclosed-amount deal that provided the underlying particle therapy capability. The company employs 51-100 staff and is led by CEO Nicolas Serandour with Chairman Michael J Sinclair; the leadership team includes dedicated roles for US operations, global manufacturing, and marketing/new business, suggesting a planned but not-yet-fully-realized international commercial footprint.

The company's business model centers on developing and (intended) sale or licensing of capital-intensive radiotherapy hardware to oncology treatment centers, hospitals, and cancer clinics — a model that inherently requires large upfront R&D and regulatory investment before any meaningful commercial revenue. Over a roughly decade-long history the company has raised approximately $53 million across three disclosed funding rounds (2013, 2017, 2022), with the 2017 round of $50.4M representing the capital peak and the 2022 round of just $1.73M a sharp step-down. No revenue, pricing, customer, product launch, or partnership data is disclosed in the source material, and no product certifications or regulatory clearances are referenced. The company's primary web domain (advancedoncotherapy.com) is listed for sale on the HugeDomains marketplace at $8,595, a signal that materially affects assessment of current operating posture and is inconsistent with active commercial scaling. Overall, the source data depicts a small, undercapitalized, pre-commercial (or near-pre-commercial) medical hardware developer whose forward trajectory will depend on capital access and successful regulatory and commercial milestones not visible in the provided evidence.

Name

Advanced Oncotherapy

Website

https://advancedoncotherapy.com

Company type

Private

Founded year

2012

Headcount range

51–100 employees

Short description

Advanced Oncotherapy is a London-based, publicly listed medical technology company (LSE: AVO) that develops advanced radiotherapy systems for cancer treatment, serving hospitals and oncology centers. It has raised approximately $53 million across three funding rounds since 2012 but discloses no revenue or commercial customers.

Ownership category

akta.pro rank

Product category

Radiation Therapy Equipment

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD), Medical Oncology (HLAKAFAB)

Keywords

• Proton beam therapy
• Particle therapy systems
• Medical linear accelerators
• Radiotherapy equipment
• Hadron therapy devices

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

Advanced Oncotherapy develops and supplies advanced radiotherapy systems, principally a compact proton beam therapy (particle therapy) system intended to treat common and rare cancers. The offering targets hospitals and oncology centers in the global particle therapy market and is positioned as a lower-cost, smaller-footprint alternative to conventional cyclotron- and synchrotron-based proton therapy installations.

Differentiator

Problem solved

Functional benefit

Products and services

• Proton beam therapy system (compact linear accelerator-based particle therapy system) Advanced radiotherapy system designed to deliver proton beam therapy for the treatment of common and rare cancers, sold to hospitals and oncology centers as a capital equipment installation.
• Linear particle accelerator radiotherapy platform Linear accelerator-based radiotherapy platform used to deliver proton beam therapy treatments, designed to reduce the size and cost of installations compared to conventional proton therapy systems.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Elekta: Swedish-headquartered incumbent in linear accelerators, brachytherapy, and radiosurgery. Competes head-to-head in the same hospital oncology market as Advanced Oncotherapy, with an established global install base and service network.
• Varian Medical Systems (Siemens Healthineers): The dominant global supplier of linear accelerators and radiation oncology software; now part of Siemens Healthineers. Directly comparable to Advanced Oncotherapy as a radiotherapy systems vendor serving cancer centers, though with vastly greater scale and a broader portfolio.
• Hitachi (Hitachi High-Tech / proton therapy): Through its Hitachi High-Tech subsidiary, Hitachi supplies proton therapy systems globally. A broad incumbent in particle therapy with established hospital installations, competing for the same customer base as Advanced Oncotherapy.

Direct peers

• Accuray: Developer and manufacturer of the CyberKnife and TomoTherapy systems for radiosurgery and radiotherapy. Direct competitor in advanced radiotherapy hardware, particularly relevant given the 16.6% CAGR projected for the CyberKnife segment Advanced Oncotherapy also addresses.
• IBA (Ion Beam Applications): Belgian leader in proton therapy systems and radiopharmaceuticals. The closest direct competitor to Advanced Oncotherapy in the proton therapy space, addressing the same particle therapy market growing at 12.4% CAGR.
• Mevion Medical Systems: US-based developer of compact proton therapy systems. Competes in the same niche of smaller, more accessible proton therapy platforms that Advanced Oncotherapy's LIGHT system targets.

Emerging players

• ViewRay: Developer of MR-guided radiation therapy systems (MRIdian). An emerging player in advanced radiotherapy with overlapping hospital oncology customers and a similar small-cap, innovation-driven profile.
• Reflexion Medical: Developer of biology-guided radiotherapy systems. Emerging entrant in advanced radiotherapy hardware targeting the same hospital oncology buyers as Advanced Oncotherapy.
• ProNova Solutions: US-based developer of compact proton therapy systems with a similar profile to Advanced Oncotherapy — a smaller, specialized entrant challenging incumbents in next-generation proton therapy hardware.

Others

• Brainlab: Provider of radiation oncology software, treatment planning, and surgical navigation. Adjacent peer in the radiotherapy ecosystem, often partnering with or complementing hardware vendors like Advanced Oncotherapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/AdvOnco_AVO
• Facebookfacebook.com/534668966
• LinkedInlinkedin.com/company/advanced-oncotherapy-plc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Oncotherapy